Receive The Newest Study Notifications

Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of...

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today...

Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

  Imeglimin met its key efficacy endpoint of HbA1c reduction, demonstrating how its unique dual mechanism of action was observed to show added efficacy benefits in combination with existing hypoglycemic agents In particular, Imeglimin was observed to demonstrate...

AVROBIO Announces First Patient Dosed Using plato™ Platform

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO (NASDAQ: AVRO) (the “Company”), a...

Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...

Bone Therapeutics advances JTA-004 into pivotal Phase III study

by Lance Smith | Dec 20, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Clinical trial application for pivotal JTA-004 Phase III study submitted Start patient enrollment anticipated early 2020 with topline results expected in Q2 2021 BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the...